91 related articles for article (PubMed ID: 3887443)
1. [Social integration of long-term paraphrenic patients with low-dose depot neuroleptic medication].
Lesch OM; Dietzel-Rogan M; Musalek M; Rajna P; Rustembegovich A; Schjerve M; Walter H
Psychiatr Prax; 1985 Mar; 12(2):63-8. PubMed ID: 3887443
[TBL] [Abstract][Full Text] [Related]
2. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Kong DS; Yeo SH
Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
4. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Brown WA; Silver MA
J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
6. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
[TBL] [Abstract][Full Text] [Related]
7. Pimozide versus fluphenazine in ambulatory schizophrenics: A 12-month comparison study.
Donlon PT; Swaback DO; Osborne ML
Dis Nerv Syst; 1977 Feb; 38(2):119-23. PubMed ID: 319967
[TBL] [Abstract][Full Text] [Related]
8. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
Knudsen P; Hansen LB; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
[TBL] [Abstract][Full Text] [Related]
9. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
Knudsen P; Hansen LB; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():41-50. PubMed ID: 3934921
[TBL] [Abstract][Full Text] [Related]
10. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
11. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
12. [Results of long-term treatment with depot neuroleptics in schizophrenic patients].
Klein A; Ehle G
Psychiatr Neurol Med Psychol (Leipz); 1988 Mar; 40(3):159-67. PubMed ID: 3132729
[TBL] [Abstract][Full Text] [Related]
13. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
[TBL] [Abstract][Full Text] [Related]
14. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
[TBL] [Abstract][Full Text] [Related]
15. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
16. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
18. Evaluations of social functioning in a 3-year double-blind investigation of pimozide versus fluphenazine in chronic schizophrenia [proceedings].
Abuzzahab FS
Psychopharmacol Bull; 1977 Jan; 13(1):71-3. PubMed ID: 319477
[No Abstract] [Full Text] [Related]
19. Fluphenazine blood levels and clinical response.
Harris PQ; Friedman MJ; Cohen BM; Cooper TB
Biol Psychiatry; 1982 Oct; 17(10):1123-30. PubMed ID: 7171656
[TBL] [Abstract][Full Text] [Related]
20. [Neuroleptic infusion therapy with high-dosed fluphenazine (author's transl)].
Fünfgeld EW; Kulhanek F
Arzneimittelforschung; 1978; 28(9):1489-91. PubMed ID: 383096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
